Transaction establishes global ownership rights of lead program and includes initial capital funding with additional optional milestone-based capital support aligned with key clinical milestones. April 24, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related diseases, today announced the successful closing of its previously announced acq

– Regulatory Filing in Japan Planned Following Clinical Trial Completion – April 24, 2026 -- Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) and Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) today announced the first patient has been dosed in a Japanese Phase 2 registrational clinical trial (jRCT2031250550) studying ziftomenib, an oral menin inhibitor, for the treatment of relapsed or refractory (R/R) NPM1-mutated (NPM1-m) acute myeloid leukemia (AML). NPM1-m AML accounts for approximately 30% of

Strategic collaboration creates a seamless US-APAC manufacturing corridor, enabling local production for global clinical trials and enhancing patient access to next-generation medicines. April 21, 2026 -- Andelyn Biosciences, ("Andelyn") a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization ("CDMO"), and ENCell Co., Ltd. ("ENCell"), a Korea-based advanced biopharmaceutical CDMO, announced today the signing of a Collaboration Agreement to establi

April 20, 2026 -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has completed its acquisition of CathWorks, a privately held medical device company, which aims to transform how coronary artery disease (CAD) is diagnosed and treated. The acquisition follows a 2022 strategic partnership with a co-promotion agreement for the CathWorks FFRangio® System where it is commercially available in the U.S., Europe and Japan. The acquisition is valued at $585 million

With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one owner Advancing felzartamab – a CD38-directed antibody with potential broad applicability across a range of immune-mediated conditions – in the Greater China Region presents an important opportunity in a key global market Agreement builds on TJ Biopharma's development success of felzartamab in China and productive clinical collaboration in Biog

The acquisition of Neurona will put UCB in both the epilepsy and cell therapy space, even as many of its fellow pharmas move away from the latter modality. UCB is fronting $650 million to absorb California-based Neurona Therapeutics to deepen its epilepsy portfolio and expand into regenerative medicine. As part of the acquisition agreement, announced Friday afternoon, UCB will also put up to $500 million on the line in milestone payments. The companies expect to consummate the transaction by t

April 13, 2026 -- Veld Pharmaceuticals GmbH (“Veld”), a Switzerland-based pharmaceutical access and services company, today announced a collaboration with Chiesi Farmaceutici S.p.A (“Chiesi”) to expand patient access to nine rare-disease therapies through a Managed Access Program (MAP) across Africa. The program is designed to enable physicians, where permitted by local regulations, to prescribe these therapies to patients with serious unmet medical needs who meet defined medical eligibility

BioOra and Cincinnati Children's unite to evaluate Atla-cel in paediatric relapsed or refractory B-ALL, building on emerging adult clinical data demonstrating markedly reduced neurotoxicity with this next-generation CAR-T therapy. BioOra and Cincinnati Children's are partnering to advance Atla-cel, a paediatric CAR‑T therapy for relapsed/refractory B‑ALL. Atla‑cel shows markedly reduced neurotoxicity in adult trials, supporting its evaluation in children who could benefit from this therapy not

April 13, 2026 -- On April 10, 2026, Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with AbbVie (NYSE: ABBV), a global biopharmaceutical company. Under the agreement, Haisco grants AbbVie the exclusive rights to develop, manufacture, and commercialize novel medicines for the treatment of pain globally, excluding mainland China, Hong Kong, and Macau. The program includes multiple compounds designed to address pain-r

Regeneron Pharmaceuticals made its first foray into radiopharmaceuticals, striking a strategic alliance with Telix Pharmaceuticals to jointly develop and commercialise next-generation radiopharmaceutical therapies across multiple solid tumour targets under a 50/50 cost and profit-sharing arrangement, with the cumulative deal value potentially reaching as much as $4.3 billion. The partnership, announced Monday, combines Telix's radiopharmaceutical development platform and global manufacturing in